TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02557035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT00835081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg Capsules
Description: 1 x 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DURICEF® capsules 500 mg
Description: 1 x 500 mg
Study: NCT00256230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram (DSF)
Description: DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
Study: NCT02362997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 monoclonal antibody
Study: NCT02891863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LEVER Acute Study System
Description: The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
Study: NCT01299935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
Study: NCT02765724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
Study: NCT02183311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - single rising dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - multiple rising dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03036748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized sodium diet
Description: Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized sodium diet
Description: Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tbl amiloride
Description: Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tbl amiloride
Description: Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
Study: NCT01309763

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE AD03
Description: s.c. injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE AD03 + Alum
Description: s.c. injection
Study: NCT00704639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Weekly intravenous carboplatin (AUC 2) for the duration of the RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended).
Study: NCT03810586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive measurement of blood pressure
Description: Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
Study: NCT03169062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gated Stationary Chest Tomosynthesis
Description: The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
Study: NCT00506831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
Study: NCT00860938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
Study: NCT01126762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Dietary advice regarding consumption of low mercury, high DHA fish

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Dietary advice regarding consumption of low mercury, high DHA fish

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Advice regarding healthful diet during pregnancy, not focused on fish intake
Study: NCT03133260

Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin
Description: Troponin will be measured before surgery and postoperative at days 1,2 and 3.

Intervention type: DRUG
Intervention: Acetylsalicylic acid
Description: 100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery

Intervention type: DRUG
Intervention: Statin
Description: 40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
Study: NCT01539239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Aqueous Implant
Description: The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: A monofocal intraocular lens (IOL) placed during the cataract surgery.
Study: NCT02407548

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme Q10 vitamin E softgel
Description: 4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme Q10 softgel
Description: 4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: placebo softgel
Description: 4 placebo softgels per day. Keep normal lift style unchanged.
Study: NCT02565160

Intervention type: PROCEDURE
Intervention: Intra-articular aspiration of Joint
Description: Procedural sampling of the joint for diagnostic purposes

Intervention type: PROCEDURE
Intervention: Intra-articular aspiration of Joint
Description: Procedural sampling of the joint for diagnostic purposes

Intervention type: PROCEDURE
Intervention: Intra-articular aspiration of Joint
Description: Procedural sampling of the joint for diagnostic purposes

Intervention type: PROCEDURE
Intervention: Joint irrigation washout
Description: Procedural washout for treatment purposes

Intervention type: PROCEDURE
Intervention: Joint irrigation washout
Description: Procedural washout for treatment purposes

Intervention type: PROCEDURE
Intervention: Total Joint Arthroplasty

Intervention type: PROCEDURE
Intervention: Revision Joint Arthroplasty

Intervention type: PROCEDURE
Intervention: Revision Joint Arthroplasty

Intervention type: PROCEDURE
Intervention: Revision Joint Arthroplasty
Study: NCT03077451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir Mesylate
Description: Given PO
Study: NCT04187872

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LITT + Pembrolizumab
Description: Each patient will undergo brain biopsy and laser interstitial thermotherapy (LITT). As soon as possible, no later than two weeks after LITT, pembrolizumab will be administered via infusion and continue q3wks for up to two years.
Study: NCT03975140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypersensitive acupoint group
Description: The first five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyposensitive acupoint group
Description: The last five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
Study: NCT03937154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT00377962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid (MPA)/azathioprine (AZA)
Description: In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
Study: NCT00959790

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetables
Description: 200 or 50 grams of vegetables daily for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetables
Description: 200 or 50 grams of vegetables daily for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: energy restriction
Description: Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
Study: NCT04709081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228
Description: ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228
Description: ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam was dosed at 2 mg (1 milliliter \[mL\] of a 2 mg/mL syrup).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
Study: NCT03442322

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transdisciplinary approach
Description: This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary approach
Description: This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
Study: NCT00377962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitors (CNI)
Description: Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
Study: NCT02487355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1 μg/ kg
Study: NCT00377962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors (CNI)
Description: Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
Study: NCT02744287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-601
Description: Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-601
Description: Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence
Study: NCT00529464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Spectroscopy
Description: Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: A standard colposcopy will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: A standard colposcopy will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: A standard colposcopy will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LEEP Procedure
Description: A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
Study: NCT01843075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous injection
Study: NCT04345874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition technical assistance
Description: Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
Study: NCT00377962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
Study: NCT02826057

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted temperature management (33 degree Celsius)
Study: NCT01796171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 MBq/kg Betalutin
Study: NCT02826057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (33 degree Celsius)
Study: NCT01282814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Hydrochloride
Description: 150 mg Extended-Release Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® XR
Description: 150 mg Extended-Release Capsule
Study: NCT01796171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 MBq/kg Betalutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 lilotomab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mBq/kg Betalutin
Study: NCT04307966

Intervention type: BEHAVIORAL
Intervention: The CIrCLE of Life Initiative
Description: HIV and obesity prevention programme delivered directly to Grade 6 preadolescents and indirectly to their parents.
Study: NCT03514147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;
Study: NCT05172180

Intervention type: DRUG
Intervention: Reamberin
Description: the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)
Study: NCT03514147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;
Study: NCT01335646

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Microdiscectomy
Description: lumbar discectomy within 1 month of randomization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories
Description: Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
Study: NCT02381158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone dipropionate
Description: Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)